On October 22, 2018, Frank Gehry, member of the Hereditary Disease Foundation Board of Directors and Founding Trustee, presented the 2019 Leslie Gehry Brenner Prize for Innovation in Science to C. Frank Bennett of Ionis Pharmaceuticals. “A few years ago my young daughter passed away from ovarian cancer,” said Mr. Gehry, “We created a fund in her name – Leslie Gehry Brenner – and we give that award every year. The idea was to give it without any strings and see what happens. I love that idea – the freedom that it implies.”
Watch the full Award presentation.
We’re excited about the beginning of a New Year and the promise 2019 holds for dramatic advances in HD research. Great things are happening…brilliant minds are at work. With your support, we will continue to push until we push HD out of the normal lifespan. Momentum begins with a moment. This is our magical moment…together we will make it happen for our families and for the future.
Read more in our January 2019 Newsletter.
"A new era for treating neurological diseases" HDF 2018 Symposium, Dr. C. Frank Bennett, Ionis
The mood within the room was electric with excitement and hope as Dr. C. Frank Bennett, senior vice president for research and franchise leader for neurological programs at Ionis Pharmaceuticals, took the podium at the Hereditary Disease Foundation October 22, 2018 Gala. He gave a mesmerizing talk
about his work developing antisense therapeutics for neuromuscular and neurological diseases. His pioneering work brought us the world’s first approved treatment for spinal muscular atrophy (SMA). In 2005, Frank started a program to develop antisense therapies for Huntington’s disease. IONIS-HTTrx is designed to treat patients with HD and is the first and only drug to demonstrate reduction of the neurotoxic abnormal huntingtin protein, the underlying cause of HD, in patients. Ionis is partnering with Roche for phase 3 of the trial, which is set to begin in the U.S. and abroad soon!! This is a groundbreaking advance for the field of HD!
Click here to watch in full to Dr. Bennett’s October 22, 2018 Symposium Presentation.
Roche/Genentech announce the locations, including 20 sites in the U.S. and 6 in Canada, for their phase 3 study - called GENERATION HD1 - to test efficacy of the huntingtin-lowering therapy RG6042.
This study is open and currently recruiting! This will be a 2-year study in people with early diagnosed HD, involving monthly spinal injections to deliver RG6042 or a placebo, as well as clinical tests and scans to understand the effect of the drug on HD symptoms. Around 660 people age 25-65 will be recruited at approximately 90 sites across the world.
Read the full press release.
With love from our Hereditary Disease Foundation family to your family!
“This is a magical moment. This is a moment when discoveries are going to really translate into better medical practice,” said Dr. Shirley Tilghman.
A rapt audience listened intently as Dr. Shirley Tilghman, president emerita and professor of molecular biology and public affairs at Princeton University, spoke about how genes are organized in the genome and regulated during early development. A member of the National Research Council’s committee that set the blueprint for the United States effort in the Human Genome Project, she was also one of the founding members of the National Advisory Council of the Human Genome Project for the National Institutes of Health. Dr. Tilghman is a world-renowned leader in the field of molecular biology whose brilliant scientific career as a mammalian development geneticist has advanced our understanding of Huntington’s disease and other disorders.
Click here to watch in full to Dr. Tilghman’s October 22, 2018 Symposium Presentation.
Research has taken a quantum leap – and with the first global clinical trial in HD poised to begin phase 3, we believe that the cure for HD is on the horizon. The Foundation’s 2018 Year in Review addresses this phenomenal breakthrough.
Together we can vanquish this disease and impact other brain disorders affecting millions of families across the world.
We've received a 4-star rating from Charity Navigator, which means we're accountable, transparent, and financially healthy! Check out our Charity Navigator profile to learn more!
We also reached the GuideStar 2018 Platinum Seal of Transparency. See our GuideStar profile.
We're committed to the highest level of transparency!
Please be sure you're on the HDF mailing list to receive the most current news and updates from us! If you don't already get emails from us, it's likely we don't have your current address. Sign up here.
Today is Giving Tuesday! Your gifts - no matter how small - have a tremendous cumulative impact on the research we are able to fund. Every penny counts!
Wishing you all a happy and HEALTHY holiday! We are extremely grateful for you!
Together we can take down this this disease and impact other brain disorders affecting millions of families across the world.
1st Row from left to right- Kristina Bowyer, Leo Sahelijo, Tiffany Baumann, Nancy Wexler, Anne Smith, Holly Kordasiewicz
2nd row left to right- Patrick Cauntay, Chrissa Dwyer (hidden), Bethany Fitzsimmons, Eric Swayze, Paul Goldberg, Rojer Lane
Eventually C. Frank Bennett, 2018 Leslie Gehry Brenner Prize for Innovation in Science recipient, steps in for a requisite Nancy Wexler hug!
Read our November 2018 Newsletter now. This month’s newsletter “Trailblazing Research…Magical Moments” highlights our recent Scientific Symposium and Leslie Gehry Brenner Prize for Innovation in Science Dinner.